Search results
22 cze 2023 · Berlin, June 22, 2023 – Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double blind parallel-group Phase III study to evaluate the efficacy and safety of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D). The primary objective of the study ...
In this webinar from SCI's Fine Chemicals Group and Young Chemists' Panel, Dr Lars Bärfacker discusses the development of dihydronaphthyridine finerenone, a therapeutic for counteracting...
David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors ...
2 wrz 2022 · Berlin, September 2, 2022 – Bayer announced today that it received approval from the U.S. Food and Drug Administration (FDA) for a label update for Kerendia™ (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
10 maj 2021 · Bayer’s Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes. Finerenone significantly reduced...
Emily Castle, PharmD, provides an evaluation of the 2022 ADA update in terms of prescribing finerenone to patients with diabetes.
16 gru 2022 · Berlin, December 16, 2022 - Bayer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending a label extension for Kerendia™ (finerenone, 10 mg or 20 mg) to include results on cardiovascular outcomes from the Phase III FIGARO-DKD study. The ...
